Khondrion Archives | Be Korea-savvy

Home / Posts tagged Khondrion

Khondrion Completes Enrolment in KHENERGYZE Phase IIb Trial Evaluating Sonlicromanol in Adult Patients with MELAS Spectrum Disorders

NIJMEGEN, the Netherlands, Jan. 10 (Korea Bizwire) — Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical study. Sonlicromanol is Khondrion’s wholly-owned, lead asset being developed to treat a range of mitochondrial diseases [...]

Khondrion Highlights Potential Role of Inflammatory Lipid Modulator Prostaglandin E2 in COVID-19 Disease and Proposes Potential Treatment Pathway with Sonlicromanol

NIJMEGEN, the Netherlands, April 15 (Korea Bizwire) – Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, has published a scientific hypothesis that the inflammatory lipid modulator, prostaglandin E2 (PGE2), may execute a prominent role in COVID-19 pathophysiology and proposes that its lead drug candidate, sonlicromanol, currently in phase IIb development to [...]

Khondrion Announces First Patients Dosed in Phase IIb Study of Sonlicromanol for Mitochondrial Diseases

NIJMEGEN, the Netherlands, Jan. 27 (Korea Bizwire) – Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its phase IIb KHENERGYZE study of Sonlicromanol (previously known as KH176), its wholly-owned lead asset in development to treat a range of mitochondrial diseases. [...]